Prof. Chi Van Dang

powered by
COS Expertise®
Johns Hopkins University
School of Medicine
Hematology
Professor
Johns Hopkins University
School of Medicine
Medicine
Hematology
Vice Dean for Research
Johns Hopkins University
School of Medicine
Medicine
Oncology Research
Johns Hopkins Family Professor
Professional Headshot of Chi Van Dang

Mailing Address

720 Rutland Avenue
Ross Research Building, Room 1032
Baltimore, Maryland 21205
United States

Contact Information

Phone: (410) 955-2773
Fax: (410) 955-0185
cvdang@jhmi.edu

Qualifications

M.D., Johns Hopkins University, Medicine, 1982.
Ph.D., Georgetown University, Chemistry, 1978.
B.S., University of Michigan, Chemistry, 1975.

Expertise and Research Interests

The Dang laboratory has contributed to the understanding of the function of the c-myc oncogene product (c-Myc), which is a helix-loop-helix-leucine zipper transcription factor. Dr. Dang’s group is identifying target genes of c-Myc and determining the significance of these target genes in tumorigenesis and cancer therapeutic responses. Over the decades abundant evidence has emerged to support a causal role for the activated cellular gene, c-myc, in animal and human tumors. In humans, the c-myc gene is activated through several mechanisms. Translocations affecting human chromosome 8, which juxtapose the c-myc proto-oncogene at 8q24 to one of three immunoglobulin genes in B-cells, activate the c-myc gene constitutively and thereby promote lymphomagenesis. The c-myc gene is amplified in various human cancers including lung carcinoma, breast carcinoma and in rare cases of colon carcinoma. In addition, elevated expression of the c-myc gene is found in a large fraction of medulloblastomas, breast and colon carcinomas. All of these neoplasms are commonly characterized by the presence of polyploidy, aneuploidy and a propensity to metabolize glucose to lactate in the presence of oxygen (aerobic glycolysis).

The Dang laboratory has contributed to the understanding of the function of the c-Myc oncoprotein, which has emerged as a central oncogenic switch in many different cancers. Dr. Dang contributions include his identification of the dimerization motif of Myc and creation of the first proto-oncogene dominant negative allele (Nature, 1989). This identification provided a tool that was used by numerous other investigators. His invention of the mammalian two-hybrid system to detect protein-protein interactions in vivo (Mol Cell Biol, 1991) has allowed him to suggest that the c-Myc protein requires a partner protein which was later cloned and termed Max. Through the same system his group later demonstrated the direct interaction of Myc and Max in living cells (Genes & Dev., 1992). This system is now used to validate and map protein-protein interaction domains and well as providing a tool for screening (PNAS, 1992). His group used yeast genetics to delineate a principle behind how helix-loop-helix proteins, such as Myc, recognize DNA (PNAS, 1992); this has now been validated repeatedly by co-crystal structures of bHLH-DNA complexes. His group and collaborators identified the interaction of p107 with c-Myc (Science, 1994; Mol Cell Biol, 1995).

His recent work focuses on the genetic program regulated by c-Myc, allowing this oncogenic transcription factor to elicit diverse cellular phenotypes. He will continue to exploit the understanding of the c-myc oncogene for therapeutic purposes. Dr. Dang's group is identifying candidate c-Myc target genes and characterizing the function of these genes in tumorigenesis. The Dang laboratory has also discovered two novel c-Myc mediated apoptotic phenotypes that have therapeutic implications. Through the discovery that c-Myc is able to activate the expression of genes involved in glycolysis (PNAS, 1997; JBC, 1999; Mol Cell Biol, 2004), they have observed that c-Myc transformed cells or cells that overexpress lactate dehydrogenase are susceptible to glucose-deprivation or 2-deoxyglucose induced apoptosis, a pathway that is p53-independent (PNAS, 1998). Whereas normal cells arrest in mitosis when exposed to microtubule inhibitors, their studies reveal that c-Myc is able to uncouple DNA synthesis from mitosis when cells are exposed to colcemid, causing cells to become polyploid and undergo apoptosis (Mol Cell Biol, 1999). They have exploited this novel phenotype and found that c-Myc protein levels in the NCI 60 cancer cell line panel correlate significantly with the sensitivity of cells to tubulin binding drugs (p < 0.001). His other contribution to translational medicine is the pivotal pre-clinical study that demonstrates the ability of a proteasome inhibitor to inhibit growth of human lymphoma in a xenograft model (Cancer Res, 1998). This approach is now shown to be significantly efficacious for the treatment of multiple myeloma.

In addition to his more translational work, Dr. Dang has shown the participation of c-Myc in the regulation of cell size (PNAS, 2000), mitochondrial homeostasis (PNAS, 2002) and mitochondrial biogenesis (Mol Cell Biol, 2005). His group also participates in the discovery a novel function for Myc in regulating a cluster of microRNAs (miRNA) that has been implicated in tumorigenesis (Nature, 2005). In particular, he has provided leadership to launch a publicly accessible database on the c-Myc cancer gene (www.myc-cancer-gene.org) funded by the National Library of Medicine (Genome Biol, 2003). With an international advisory board, Dr. Dang has provided a searchable Myc target gene database that characterizes each putative target according to the level of experiment support. This is particularly important as the number of studies using DNA microarray or SAGE increase yearly. Using the database and his group’s creation of SChIP (scanning chromatin immunoprecipitation) (JBC, 2001), his team is able to combine informatics and experimental approaches for the rapid, accurate validation of the direct binding of the Myc transcription factor to predicted genomic binding sites (PNAS, 2003 and Genome Biol, 2003). The MYC website will also launch a database on alterations of MYC in human cancers as well as a Myc protein-protein interaction database. This website provides a model for the much needed integration of vast amounts of molecular biological and genetic information on key molecules and pathways.

Dr. Dang provides leadership to his institution (as Vice Dean for Research at the School of Medicine and Chair of the Johns Hopkins Institute for Cell Engineering Operating Committee) and to the scientific community (Senior Editor, Cancer Research; editorial boards of Journal of Clinical Investigation, Drug Discovery Today and Neoplasia). Dr. Dang is the inaugural recipient of The Johns Hopkins Family Professorship in Oncology Research. He also serves as a member of the National Cancer Institute Board of Scientific Counselors and was president of the American Society for Clinical Investigation (2003). Dr. Dang has sponsored 12 KO8 physician-scientist awardees and mentored 11 Ph.D. doctorates. Previous trainees have established careers in biomedical research elsewhere or at Hopkins.

Other Expertise

NIH Oncological Sciences - Pathology B Study Section (Charter Member, 1993-1997)
2000-2005 National Cancer Institute Board of Scientific Counselors

Editorial Boards:
Journal of Clinical Investigation 1998-
Neoplasia 1999-
Cancer Research, Associate Editor 2000-, Senior Editor 2002-
Vietnamese Medical Journal 2001-
Drug Discovery Today-Disease Mechanisms 2004-
Current Cancer Therapy Reviews 2004-
Molecular and Cellular Biology 2006-
Journal of Molecular Medicine, Associate Editor 2006-

Industrial Relevance

Cancer small molecule therapeutics
Cancer glucose metabolism

Keywords

COS Keywords:

Cancer Or Carcinogenesis, Hematology, Medical Genetics, Molecular Genetics, Oncology, Proteins and Macromolecules, Recombinant Dna.

Additional Terms:

Cancer, Carcinogenesis, Gene Product, Hematology, Molecular Genetics, Oncology, Protein Expression, Protein Purification, Protein-protein Interaction, Recombinant DNA.

Languages

(Reading, Writing, Speaking)

Vietnamese: (Basic, Basic, Functional)
French: (Basic, Basic, None)

Memberships

American Association for Cancer Research
American Society for Clinical Investigation
American Society of Hematology
American Society of Microbiology
Association of American Physicians

Honors and Awards

2006, Member, Institute of Medicine, National Academies
2005, Johns Hopkins Family Professorship in Oncology Research, Johns Hopkins University, School of Medicine
2005, VANG Golden Torch Award, Vietnamese-American National Gala, Viet Heritage Society
2004, Mark Brothers Distinguished Lecturer, Indiana University, School of Medicine
2002-2003, President, American Society for Clinical Investigation
2000, Odyssey Program Distinguished Lecturer, MD Anderson Cancer Center
1999, Merit Award, National Institutes of Health, Johns Hopkins University
1997, Member, Association of American Physicians, Johns Hopkins University
1997, Stohlman Scholar, Leukemia Society of America, Johns Hopkins University
1997-2002, Member, Interurban Clinical Club, Johns Hopkins University
1993, Member, American Society for Clinical Investigation, Johns Hopkins University
1992-1997, Leukemia Society of America Scholar, Johns Hopkins University
1989, Stratton Foundation Award, Henry M. and Lillian Stratton Foundation, Johns Hopkins University
1989-1992, ACS Junior Faculty Award, American Cancer Society, Johns Hopkins University
1987, ACS Senior Fellow, American Cancer Society, University of California, San Francisco
1983, Schwentker Research Award, Johns Hopkins University, Young Investigator's Day
1982, Phi Beta Kappa, Johns Hopkins University
1982, Alpha Omega Alpha, Johns Hopkins University
1978, Zorbach Award, Chemistry Department, Georgetown University, Dissertation Award
1974, Gomberg Fellowship, University of Michigan, University of Michigan, Chemistry fellow
1974, Phi Lambda Upsilon, University of Michigan, Chemistry Honor Society
1973, William Branstrom Prize, University of Michigan, University of Michigan, Freshman prize

Funding Received

  • National Institutes of Health (NIH): c-Myc targets in the pathogenesis of human cancers, 1992 to 2010.
  • National Institutes of Health (NIH): Myc: Transcription and Interaction with p107, 1990 to 2007.
  • National Institutes of Health (NIH): Training Program in Hematology, 1982 to 2008.

Publications

  • O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT, C-Myc-regulated MicroRNAs Modulate E2F1 Expression., Nature, 435(7043), 839-43, Jun 2005 Abstract
  • Barrett JF, Lee LA, Dang CV, Stimulation of Myc Transactivation By the TATA Binding Protein In Promoter-reporter Assays., Bmc Biochemistry [electronic Resource], 6(1), 7, May 2005 Abstract
  • Kim JW, Dang CV, Multifaceted Roles of Glycolytic Enzymes., Trends in Biochemical Sciences, 30(3), 142-50, Mar 2005 Abstract
  • Chou WC, Dang CV, Acute Promyelocytic Leukemia: Recent Advances in Therapy and Molecular Basis of Response to Arsenic Therapies., Current Opinion in Hematology, 12(1), 1-6, Jan 2005 Abstract
  • Perry ME, Dang CV, Hockenbery D, Moll U, Highlights of the National Cancer Institute Workshop on Mitochondrial Function and Cancer., Cancer Research, 64(20), 7640-4, Oct 2004 Abstract
  • Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV, Evaluation of Myc E-box Phylogenetic Footprints in Glycolytic Genes By Chromatin Immunoprecipitation Assays., Molecular and Cellular Biology, 24(13), 5923-36, Jul 2004 Abstract
  • Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC, Histopathological and Molecular Prognostic Markers in Medulloblastoma: C-myc, N-myc, TrkC, and Anaplasia., Journal of Neuropathology and Experimental Neurology, 63(5), 441-9, May 2004 Abstract
  • Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV, Role of NADPH Oxidase in Arsenic-induced Reactive Oxygen Species Formation and Cytotoxicity in Myeloid Leukemia Cells., Proceedings of the National Academy of Sciences of the United States of America., 101(13), 4578-83, Mar 2004 Abstract
  • Elkon R, Zeller KI, Linhart C, Dang CV, Shamir R, Shiloh Y, In Silico Identification of Transcriptional Regulators Associated With C-Myc., Nucleic Acids Research, 32(17), 4955-61, 2004 Abstract
  • Dang CV, Celebrating the Physician-scientist., The Journal of Clinical Investigation, 112(12), S1-2, Dec 2003 Abstract
  • Gardner LB, Li F, Yang X, Dang CV, Anoxic Fibroblasts Activate a Replication Checkpoint That Is Bypassed By E1a., Molecular and Cellular Biology, 23(24), 9032-45, Dec 2003 Abstract
  • Ulanet DB, Torbenson M, Dang CV, Casciola-Rosen L, Rosen A, Unique Conformation of Cancer Autoantigen B23 in Hepatoma: a Mechanism For Specificity in the Autoimmune Response., Proceedings of the National Academy of Sciences of the United States of America., 100(21), 12361-6, Oct 2003 Abstract
  • Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, Surendranath V, Niranjan V, Muthusamy B, Gandhi TK, Gronborg M, Ibarrola N, Deshpande N, Shanker K, Shivashankar HN, Rashmi BP, Ramya MA, Zhao Z, Chandrika KN, Padma N, Harsha HC, Yatish AJ, Kavitha MP, Menezes M, Choudhury DR, Suresh S, Ghosh N, Saravana R, Chandran S, Krishna S, Joy M, Anand SK, Madavan V, Joseph A, Wong GW, Schiemann WP, Constantinescu SN, Huang L, Khosravi-Far R, Steen H, Tewari M, Ghaffari S, Blobe GC, Dang CV, Garcia JG, Pevsner J, Jensen ON, Roepstorff P, Deshpande KS, Chinnaiyan AM, Hamosh A, Chakravarti A, Pandey A, Development of Human Protein Reference Database As An Initial Platform For Approaching Systems Biology in Humans., Genome Research, 13(10), 2363-71, Oct 2003 Abstract
  • Fan X, Wang Y, Kratz J, Brat DJ, Robitaille Y, Moghrabi A, Perlman EJ, Dang CV, Burger PC, Eberhart CG, HTERT Gene Amplification and Increased MRNA Expression in Central Nervous System Embryonal Tumors., The American Journal of Pathology, 162(6), 1763-9, Jun 2003 Abstract
  • Johnson SA, Dubeau L, Kawalek M, Dervan A, Schonthal AH, Dang CV, Johnson DL, Increased Expression of TATA-binding Protein, the Central Transcription Factor, Can Contribute to Oncogenesis., Molecular and Cellular Biology, 23(9), 3043-51, May 2003 Abstract
  • Haggerty TJ, Zeller KI, Osthus RC, Wonsey DR, Dang CV, A Strategy for Identifying Transcription Factor Binding Sites Reveals Two Classes of Genomic C-Myc Target Sites., Proceedings of the National Academy of Sciences of the United States of America., 100(9), 5313-8, Apr 2003 Abstract
  • Kenedy AA, Cohen KJ, Loveys DA, Kato GJ, Dang CV, Identification and Characterization of the Novel Centrosome-associated Protein CCCAP., Gene, 303, 35-46, Jan 2003 Abstract
  • Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV, An Integrated Database of Genes Responsive to the Myc Oncogenic Transcription Factor: Identification of Direct Genomic Targets., Genome Biology, 4(10), R69, 2003 Abstract
  • Wonsey DR, Zeller KI, Dang CV, The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation, Proceedings of the National Academy of Sciences (USA), 99(10), 6649-54, May 2002 Abstract
  • Prescott JE, Osthus RC, Lee LA, Lewis BC, Shim H, Barrett JF, Guo Q, Hawkins AL, Griffin CA, Dang CV, A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation, Journal of Biological Chemistry, 276(51), 48276-84, December 2001 Abstract
  • Zeller KI, Haggerty TJ, Barrett JF, Guo Q, Wonsey DR, Dang CV, Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation, Journal of Biological Chemistry, 276(51), 48285-91, December 2001 Abstract
  • Boxer LM, Dang CV, Translocations involving c-myc and c-myc function, Oncogene, 20(40), 5595-610, September 2001 Abstract
  • Kuttler F, Ame P, Clark H, Haughey C, Mougin C, Cahn JY, Dang CV, Raffeld M, Fest T, c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli, Oncogene, 20(42), 6084-94, September 2001 Abstract
  • Dang CV, Runner's anemia, JAMA: The Journal of the American Medical Association, 286(6), 714-6, August 2001 Abstract
  • Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV, Hypoxia inhibits G1/S transition through regulation of p27 expression, Journal of Biological Chemistry, 276(11), 7919-26, March 2001 Abstract
  • Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ, Dang CV, Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A, Cancer Research, 60(21), 6178-83, November 2000 Abstract
  • Kim S, Li Q, Dang CV, Lee LA, Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo, Proceedings of the National Academy of Sciences (USA), 97(21), 11198-202, October 2000 Abstract
  • Barr LF, Campbell SE, Diette GB, Gabrielson EW, Kim S, Shim H, Dang CV, c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression., Cancer Research, 60(1), 143-9, 1 2000 Abstract
  • Li Q, Dang CV, c-Myc overexpression uncouples DNA replication from mitosis., Molecular and Cellular Biology, 19(8), 5339-51, August 1999 Abstract
  • Kolligs FT, Hu G, Dang CV, Fearon ER, Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression., Molecular and Cellular Biology, 19(8), 5696-706, August 1999 Abstract
  • Dang C V, Gerson S L, Litwak M, Padarathsingh M, Gene therapy and translational cancer research, CLINICAL CANCER RESEARCH, 5(2), 471-4, 1999 Abstract
  • Dang C V, Semenza G L, Oncogenic alterations of metabolism, TRENDS IN BIOCHEMICAL SCIENCES, 24(2), 68-72, 1999 Abstract
  • Dang CV, Gerson SL, Litwak M, Padarathsingh M, Gene therapy and translational cancer research., Clinical Cancer Research, 5(2), 471-4, February 1999 Abstract
  • Dang CV, Semenza GL, Oncogenic alterations of metabolism., Trends in Biochemical Sciences, 24(2), 68-72, February 1999 Abstract
  • Dang C V, c-Myc target genes involved in cell growth, apoptosis, and metabolism, MOLECULAR AND CELLULAR BIOLOGY, 19(1), 1-11, 1999 Abstract
  • Dang CV, c-Myc target genes involved in cell growth, apoptosis, and metabolism., Molecular and Cellular Biology, 19(1), 1-11, Jan 1999 Abstract
  • Brodsky R A, Petri M, Smith B D, Seifter E J, Spivak J L, Styler M, Dang C V, Brodsky I, Jones R J, Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease, ANNALS OF INTERNAL MEDICINE, 129(12), 1031-5, 15 1998 Abstract
  • Barr L F, Campbell S E, Bochner B S, Dang C V, Association of the decreased expression of alpha3beta1 integrin with the altered cell: environmental interactions and enhanced soft agar cloning ability of c-myc-overexpressing small cell lung cancer, CANCER RESEARCH, 58(23), 5537-45, 1 1998 Abstract
  • Barr LF, Campbell SE, Bochner BS, Dang CV, Association of the decreased expression of alpha3beta1 integrin with the altered cell: environmental interactions and enhanced soft agar cloning ability of c-myc-overexpressing small cell lung cancer, Cancer Research, 58(23), 5537-45, 1 Dec 1998 Abstract
  • Jin Y, Wilhide C C, Dang C, Li L, Li S X, Villa-Garcia M, Bray P F, Human integrin beta3 gene expression: evidence for a megakaryocytic cell-specific cis-acting element, BLOOD, 92(8), 2777-90, 15 1998 Abstract
  • Orlowski R Z, Eswara J R, Lafond-Walker A, Grever M R, Orlowski M, Dang C V, Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor, CANCER RESEARCH, 58(19), 4342-8, 1 1998 Abstract
  • Lin K I, Chattopadhyay N, Bai M, Alvarez R, Dang C V, Baraban J M, Brown E M, Ratan R R, Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 249(2), 325-31, 19 1998 Abstract
  • Shim H, Chun Y S, Lewis B C, Dang C V, A unique glucose-dependent apoptotic pathway induced by c-Myc, Proceedings of the National Academy of Sciences (USA), 95(4), 1511-6, 17 1998 Abstract
  • Shim H, Chun YS, Lewis BC, Dang CV, A unique glucose-dependent apoptotic pathway induced by c-Myc., Proceedings of the National Academy of Sciences (USA), 95(4), 1511-6, 17 1998 Abstract
  • Pangilinan F, Li Q, Weaver T, Lewis B C, Dang C V, Spencer F, Mammalian BUB1 protein kinases: map positions and in vivo expression, GENOMICS, 46(3), 379-88, 15 1997 Abstract
  • Wechsler D S, Shelly C A, Petroff C A, Dang C V, MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells, CANCER RESEARCH, 57(21), 4905-12, 1 1997 Abstract
  • Lewis B C, Shim H, Li Q, Wu C S, Lee L A, Maity A, Dang C V, Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene, MOLECULAR AND CELLULAR BIOLOGY, 17(9), 4967-78, 1997 Abstract
  • Alvarez R J, Gips S J, Moldovan N, Wilhide C C, Milliken E E, Hoang A T, Hruban R H, Silverman H S, Dang C V, Goldschmidt-Clermont P J, 17beta-estradiol inhibits apoptosis of endothelial cells, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 237(2), 372-81, 18 1997 Abstract
  • Dang C V, Lewis B C, Dolde C, Dang G, Shim H, Oncogenes in tumor metabolism, tumorigenesis, and apoptosis, JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 29(4), 345-54, 1997 Abstract
  • Dang CV, Lewis BC, Dolde C, Dang G, Shim H, Oncogenes in tumor metabolism, tumorigenesis, and apoptosis., Journal of Bioenergetics and Biomembranes, 29(4), 345-54, 1997 Abstract
  • Yano T, Nakamura T, Blechman J, Sorio C, Dang C V, Geiger B, Canaani E, Nuclear punctate distribution of ALL-1 is conferred by distinct elements at the N terminus of the protein., Proceedings of the National Academy of Sciences (USA), 94(14), 7286-91, 8 Jul 1997 Abstract
  • Shim H, Dolde C, Lewis B C, Wu C S, Dang G, Jungmann R A, Dalla-Favera R, Dang C V, c-Myc transactivation of LDH-A: implications for tumor metabolism and growth, Proceedings of the National Academy of Sciences (USA), 94(13), 6658-63, 24 1997 Abstract
  • Lee L A, Dang C V, C-Myc transrepression and cell transformation, CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, 224(0070-217X), 131-5, 1997 Abstract
  • Shim H, Lewis B C, Dolde C, Li Q, Wu C S, Chun Y S, Dang C V, Myc target genes in neoplastic transformation, CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, 224(0070-217X), 181-90, 1997 Abstract
  • Lee L A, Dolde C, Barrett J, Wu C S, Dang C V, A link between c-Myc-mediated transcriptional repression and neoplastic transformation, JOURNAL OF CLINICAL INVESTIGATION, 97(7), 1687-95, 1 1996 Abstract
  • Wechsler D S, Shelly C A, Dang C V, Genomic organization of human MXI1, a putative tumor suppressor gene, GENOMICS, 32(3), 466-70, 15 1996 Abstract
  • Mol P C, Wang R H, Batey D W, Lee L A, Dang C V, Berger S L, Do products of the myc proto-oncogene play a role in transcriptional regulation of the prothymosin alpha gene, MOLECULAR AND CELLULAR BIOLOGY, 15(12), 6999-7009, 1995 Abstract
  • Chou T Y, Hart G W, Dang C V, c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas, JOURNAL OF BIOLOGICAL CHEMISTRY, 270(32), 18961-5, 11 1995 Abstract
  • Hoang A T, Lutterbach B, Lewis B C, Yano T, Chou T Y, Barrett J F, Raffeld M, Hann S R, Dang C V, A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain, MOLECULAR AND CELLULAR BIOLOGY, 15(8), 4031-42, 1995 Abstract
  • Barrett J F, Lewis B C, Hoang A T, Alvarez R J, Dang C V, Cyclin A links c-Myc to adhesion-independent cell proliferation, JOURNAL OF BIOLOGICAL CHEMISTRY, 270(27), 15923-5, 7 1995 Abstract
  • Wilhide C C, Van Dang C, Dipersio J, Kenedy A A, Bray P F, Overexpression of cyclin D1 in the Dami megakaryocytic cell line causes growth arrest., Blood, 86(1), 294-304, 1 Jul 1995 Abstract
  • Chou T Y, Dang C V, Hart G W, Glycosylation of the c-Myc transactivation domain, Proceedings of the National Academy of Sciences (USA), 92(10), 4417-21, 9 1995 Abstract
  • Lee L A, Resar L M, Dang C V, Cell density and paradoxical transcriptional properties of c-Myc and Max in cultured mouse fibroblasts, JOURNAL OF CLINICAL INVESTIGATION, 95(2), 900-4, 1995 Abstract
  • Lee LA, Resar LM, Dang CV, Cell density and paradoxical transcriptional properties of c-Myc and Max in cultured mouse fibroblasts., Journal of Clinical Investigation, 95(2), 900-4, 1995 Abstract
  • Raffeld M, Yano T, Hoang A T, Lewis B, Clark H M, Otsuki T, Dang C V, Clustered mutations in the transcriptional activation domain of Myc in 8q24 translocated lymphomas and their functional consequences, CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, 194(0070-217X), 265-72, 1995 Abstract
  • Bova G S, Wechsler D S, Van Dang C, Isaacs W B, TaqI polymorphism of the human MXI1 gene., Human Molecular Genetics, 3(12), 2266, December 1994 Abstract
  • Hoang A T, Cohen K J, Barrett J F, Bergstrom D A, Dang C V, Participation of cyclin A in Myc-induced apoptosis, Proceedings of the National Academy of Sciences (USA), 91(15), 6875-9, 19 1994 Abstract
  • Wechsler D S, Papoulas O, Dang C V, Kingston R E, Differential binding of c-Myc and Max to nucleosomal DNA, MOLECULAR AND CELLULAR BIOLOGY, 14(6), 4097-107, 1994 Abstract
  • Wechsler D S, Hawkins A L, Li X, Jabs E W, Griffin C A, Dang C V, Localization of the human Mxi1 transcription factor gene (MXI1) to chromosome 10q24-q25, GENOMICS, 21(3), 669-72, 1994 Abstract
  • Gu W, Bhatia K, Magrath I T, Dang C V, Dalla-Favera R, Binding and suppression of the Myc transcriptional activation domain by p107., Science, 264(5156), 251-4, 8 Apr 1994 Abstract
  • Resar L M, Dolde C, Barrett J F, Dang C V, B-myc inhibits neoplastic transformation and transcriptional activation by c-myc, MOLECULAR AND CELLULAR BIOLOGY, 13(2), 1130-6, 1993 Abstract
  • Finkel T, Duc J, Fearon E R, Dang C V, Tomaselli G F, Detection and modulation in vivo of helix-loop-helix protein-protein interactions., Journal of Biological Chemistry, 268(1), 5-8, 5 Jan 1993 Abstract
  • Fearon E R, Finkel T, Gillison M L, Kennedy S P, Casella J F, Tomaselli G F, Morrow J S, Van Dang C, Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells., Proceedings of the National Academy of Sciences (USA), 89(17), 7958-62, 1 Sep 1992 Abstract
  • Kato G J, Dang C V, Function of the c-Myc oncoprotein, FASEB JOURNAL, 6(12), 3065-72, 1992 Abstract
  • Wechsler D S, Dang C V, Opposite orientations of DNA bending by c-Myc and Max, Proceedings of the National Academy of Sciences (USA), 89(16), 7635-9, 15 1992 Abstract
  • Barrett J, Birrer M J, Kato G J, Dosaka-Akita H, Dang C V, Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells, MOLECULAR AND CELLULAR BIOLOGY, 12(7), 3130-7, 1992 Abstract
  • Dang C V, Myelodysplastic syndrome clinical conference, JAMA, 267(15), 2077-80, 15 1992 Abstract
  • Dang C V, Dolde C, Gillison M L, Kato G J, Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins, Proceedings of the National Academy of Sciences (USA), 89(2), 599-602, 15 1992 Abstract
  • Kato G J, Wechsler D S, Dang C V, DNA binding by the Myc oncoproteins, CANCER TREATMENT AND RESEARCH, 63(0927-3042), 313-25, 1992 Abstract
  • Kato G J, Lee W M, Chen L L, Dang C V, Max: functional domains and interaction with c-Myc, GENES AND DEVELOPMENT, 6(1), 81-92, 1992 Abstract
  • Dang C V, c-myc oncoprotein function, BIOCHIMICA ET BIOPHYSICA ACTA, 1072(2-3), 103-13, 10 1991 Abstract
  • Potter J J, Cheneval D, Dang C V, Resar L M, Mezey E, Yang V W, The upstream stimulatory factor binds to and activates the promoter of the rat class I alcohol dehydrogenase gene, JOURNAL OF BIOLOGICAL CHEMISTRY, 266(23), 15457-63, 15 1991 Abstract
  • Dang C V, Barrett J, Villa-Garcia M, Resar L M, Kato G J, Fearon E R, Intracellular leucine zipper interactions suggest c-Myc hetero-oligomerization, MOLECULAR AND CELLULAR BIOLOGY, 11(2), 954-62, 1991 Abstract
  • O'Rourke R W, Miller C W, Kato G J, Simon K J, Chen D L, Dang C V, Koeffler H P, A potential transcriptional activation element in the p53 protein., Oncogene, 5(12), 1829-32, December 1990 Abstract
  • Bantia S, Mane S M, Bell W R, Dang C V, Fibrinogen Baltimore I: polymerization defect associated with a gamma 292Gly----Val (GGC----GTC) mutation, BLOOD, 76(11), 2279-83, 1 1990 Abstract
  • Kato G J, Barrett J, Villa-Garcia M, Dang C V, An amino-terminal c-myc domain required for neoplastic transformation activates transcription, MOLECULAR AND CELLULAR BIOLOGY, 10(11), 5914-20, 1990 Abstract
  • Freytag S O, Dang C V, Lee W M, Definition of the activities and properties of c-myc required to inhibit cell differentiation., Cell Growth and Differentiation, 1(7), 339-43, July 1990 Abstract
  • Bantia S, Bell W R, Dang C V, Polymerization defect of fibrinogen Baltimore III due to a gamma Asn308----Ile mutation, BLOOD, 75(8), 1659-63, 15 1990 Abstract
  • Dang C V, Lee W M, Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins., Journal of Biological Chemistry, 264(30), 18019-23, 25 Oct 1989 Abstract
  • Dang C V, Shin C K, Bell W R, Nagaswami C, Weisel J W, Fibrinogen sialic acid residues are low affinity calcium-binding sites that influence fibrin assembly., Journal of Biological Chemistry, 264(25), 15104-8, 5 Sep 1989 Abstract
  • Dang C V, McGuire M, Buckmire M, Lee W M, Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein., Nature, 337(6208), 664-6, 16 Feb 1989 Abstract
  • Dang C V, Oncogenes and proto-oncogenes: general concepts., Cancer Treatment and Research, 47, 1-24, 1989 Abstract
  • Lee L.A., Resar L.M.S., Dang C.V.: Cell density and paradoxical transcriptional properties of c-Myc and Max in cultured mouse fibroblasts. J Clin Invest, 95:900-905, 1995
  • Barrett J.F., Lewis B.C., Hoang A.T., Alvarez Jr R.J., Dang C.V.: Cyclin A links c-Myc to adhesion-independent cell proliferation. J Biol Chem, 270:15923-15925, 1995
  • Hoang AT, Lutterbach B, Lewis BC, Yano T, Chou T-Y, Barrett JF, Raffeld M, Hann SR, Dang CV: A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107 and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol, 8:4031-4042, 1995

Profile Details

Last Updated: 10/19/2007

COS Expertise ID #261077
Reference this profile directly: http://myprofile.cos.com/cvdang